{"pmid":32194995,"pmcid":"PMC7060195","title":"The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines.","text":["The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines.","The outbreak of 2019-novel coronavirus disease (COVID-19) that is caused by SARS-CoV-2 has spread rapidly in China, and has developed to be a Public Health Emergency of International Concern. However, no specific antiviral treatments or vaccines are available yet. This work aims to share strategies and candidate antigens to develop safe and effective vaccines against SARS-CoV-2.","NPJ Vaccines","Shang, Weilong","Yang, Yi","Rao, Yifan","Rao, Xiancai","32194995"],"abstract":["The outbreak of 2019-novel coronavirus disease (COVID-19) that is caused by SARS-CoV-2 has spread rapidly in China, and has developed to be a Public Health Emergency of International Concern. However, no specific antiviral treatments or vaccines are available yet. This work aims to share strategies and candidate antigens to develop safe and effective vaccines against SARS-CoV-2."],"journal":"NPJ Vaccines","authors":["Shang, Weilong","Yang, Yi","Rao, Yifan","Rao, Xiancai"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32194995","week":"202012|Mar 16 - Mar 22","doi":"10.1038/s41541-020-0170-0","keywords":["Infection","Microbiology","Pathogenesis","Vaccines"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661818360696930304,"score":6.891626,"similar":[{"pmid":32108359,"title":"Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.","text":["Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.","Recently, a novel coronavirus (SARS-COV-2) emerged which is responsible for the recent outbreak in Wuhan, China. Genetically, it is closely related to SARS-CoV and MERS-CoV. The situation is getting worse and worse, therefore, there is an urgent need for designing a suitable peptide vaccine component against the SARS-COV-2. Here, we characterized spike glycoprotein to obtain immunogenic epitopes. Next, we chose 13 Major Histocompatibility Complex-(MHC) I and 3 MHC-II epitopes, having antigenic properties. These epitopes are usually linked to specific linkers to build vaccine components and molecularly dock on toll-like receptor-5 to get binding affinity. Therefore, to provide a fast immunogenic profile of these epitopes, we performed immunoinformatics analysis so that the rapid development of the vaccine might bring this disastrous situation to the end earlier.","J Med Virol","Bhattacharya, Manojit","Sharma, Ashish R","Patra, Prasanta","Ghosh, Pratik","Sharma, Garima","Patra, Bidhan C","Lee, Sang-Soo","Chakraborty, Chiranjib","32108359"],"abstract":["Recently, a novel coronavirus (SARS-COV-2) emerged which is responsible for the recent outbreak in Wuhan, China. Genetically, it is closely related to SARS-CoV and MERS-CoV. The situation is getting worse and worse, therefore, there is an urgent need for designing a suitable peptide vaccine component against the SARS-COV-2. Here, we characterized spike glycoprotein to obtain immunogenic epitopes. Next, we chose 13 Major Histocompatibility Complex-(MHC) I and 3 MHC-II epitopes, having antigenic properties. These epitopes are usually linked to specific linkers to build vaccine components and molecularly dock on toll-like receptor-5 to get binding affinity. Therefore, to provide a fast immunogenic profile of these epitopes, we performed immunoinformatics analysis so that the rapid development of the vaccine might bring this disastrous situation to the end earlier."],"journal":"J Med Virol","authors":["Bhattacharya, Manojit","Sharma, Ashish R","Patra, Prasanta","Ghosh, Pratik","Sharma, Garima","Patra, Bidhan C","Lee, Sang-Soo","Chakraborty, Chiranjib"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32108359","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25736","keywords":["SARS-COV-2","epitopes","immunoinformatics","vaccine"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647484805121,"score":88.1351},{"pmid":32196410,"title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia.","text":["Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia.","Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed.","Emerg Microbes Infect","Lin, Ling","Lu, Lianfeng","Cao, Wei","Li, Taisheng","32196410"],"abstract":["Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed."],"journal":"Emerg Microbes Infect","authors":["Lin, Ling","Lu, Lianfeng","Cao, Wei","Li, Taisheng"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196410","week":"202012|Mar 16 - Mar 22","doi":"10.1080/22221751.2020.1746199","keywords":["Anticoagulation","COVID-19","IVIg","Pathogenesis","SARS-CoV-2"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661818360703221760,"score":84.76543},{"pmid":32162456,"title":"Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.","text":["Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.","The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. Along these efforts, the structure of SARS-CoV-2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform - Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS-CoV-2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community.","Mol Inform","Ton, Anh-Tien","Gentile, Francesco","Hsing, Michael","Ban, Fuqiang","Cherkasov, Artem","32162456"],"abstract":["The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. Along these efforts, the structure of SARS-CoV-2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform - Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS-CoV-2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community."],"journal":"Mol Inform","authors":["Ton, Anh-Tien","Gentile, Francesco","Hsing, Michael","Ban, Fuqiang","Cherkasov, Artem"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32162456","week":"202011|Mar 09 - Mar 15","doi":"10.1002/minf.202000028","keywords":["COVID-19","Deep learning","SARS-CoV-2","protease inhibitors","virtual screening"],"source":"PubMed","locations":["ZINC15"],"topics":["Treatment"],"weight":1,"_version_":1661359647894798338,"score":81.940865},{"pmid":32186952,"title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.","text":["COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.","The novel coronavirus infection (COVID-19 or Coronavirus disease 2019) that emerged from Wuhan, Hubei province of China has spread to many countries worldwide. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS in the past decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt this emerging virus infection.","Hum Vaccin Immunother","Dhama, Kuldeep","Sharun, Khan","Tiwari, Ruchi","Dadar, Maryam","Malik, Yashpal Singh","Singh, Karam Pal","Chaicumpa, Wanpen","32186952"],"abstract":["The novel coronavirus infection (COVID-19 or Coronavirus disease 2019) that emerged from Wuhan, Hubei province of China has spread to many countries worldwide. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS in the past decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt this emerging virus infection."],"journal":"Hum Vaccin Immunother","authors":["Dhama, Kuldeep","Sharun, Khan","Tiwari, Ruchi","Dadar, Maryam","Malik, Yashpal Singh","Singh, Karam Pal","Chaicumpa, Wanpen"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32186952","week":"202012|Mar 16 - Mar 22","doi":"10.1080/21645515.2020.1735227","keywords":["COVID-19","Emerging coronavirus","drugs","therapeutics","vaccines"],"source":"PubMed","locations":["Hubei","China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661633092392058881,"score":80.99249},{"pmid":32110875,"title":"Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.","text":["Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.","Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence.","J Clin Med","Pang, Junxiong","Wang, Min Xian","Ang, Ian Yi Han","Tan, Sharon Hui Xuan","Lewis, Ruth Frances","Chen, Jacinta I-Pei","Gutierrez, Ramona A","Gwee, Sylvia Xiao Wei","Chua, Pearleen Ee Yong","Yang, Qian","Ng, Xian Yi","Yap, Rowena Ks","Tan, Hao Yi","Teo, Yik Ying","Tan, Chorh Chuan","Cook, Alex R","Yap, Jason Chin-Huat","Hsu, Li Yang","32110875"],"abstract":["Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence."],"journal":"J Clin Med","authors":["Pang, Junxiong","Wang, Min Xian","Ang, Ian Yi Han","Tan, Sharon Hui Xuan","Lewis, Ruth Frances","Chen, Jacinta I-Pei","Gutierrez, Ramona A","Gwee, Sylvia Xiao Wei","Chua, Pearleen Ee Yong","Yang, Qian","Ng, Xian Yi","Yap, Rowena Ks","Tan, Hao Yi","Teo, Yik Ying","Tan, Chorh Chuan","Cook, Alex R","Yap, Jason Chin-Huat","Hsu, Li Yang"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32110875","week":"20209|Feb 24 - Mar 01","doi":"10.3390/jcm9030623","keywords":["MERS-CoV","SARS-CoV","diagnostics","global health","novel coronavirus","outbreak","treatments","vaccine"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647964004352,"score":80.9718}]}